Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy (IgAN)

NCT00549692 Phase 3 COMPLETED

The purpose of this study is to compare omega-3 fatty acids with placebo for efficacy in retardation of increase of serum creatinine(SCr) in IgA Nephropathy

Details

Lead sponsor	Kuhnil Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	COMPLETED
Enrolment	152
Start date	2007-11
Completion	2012-09

Conditions

• IgA Nephropathy

Interventions

• Omega-3 fatty acid ethylester90

Primary outcomes

• The rate of number of patients that 50% or more increase in SCr after 42 months — 42 months

Countries

South Korea